Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

Executive Summary

With tensions rising in the first-line NSCLC space, AstraZeneca's update on the analysis plan of its Phase III MYSTIC trial has analysts reassessing the firm’s chances against stiff competition.


Related Content

AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon
Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind
Running The Drug Catalyst Gauntlet: What To Look For In Q2 2017
Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study
Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts